AllSight
Companies · ERAS · Pharmaceutical Preparations

Erasca, Inc. (ERAS)

Erasca, Inc. (ERAS) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Erasca, Inc. (ERAS) stock — financials & valuation

Key numbers for Erasca, Inc. (ERAS): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 28/100 — a percentile rank of Erasca, Inc.’s fundamentals against Manufacturing peers, weakest on profitability. A quality ranking, not a price prediction.

Market cap$5.1B
EV / EBITDA-16.9×
Return on equity-79.4%
ROIC-94.8%
Debt / equity0.0×
Dividend yield0.0%

Is Erasca, Inc. overvalued? P/B looks overvalued vs its 5-year range.

Independent of the events above — derived from Erasca, Inc.’s own financial statements and shown as context, never as advice.

Aug 24, 2026Fast Track designation
Erasca wins Fast Track for ERAS-0015, but approval odds are unchanged
Aug 11, 2026
Promising ERAS-0015 update was largely old news; loss missed estimates
Aug 10, 2026
Veteran oncology leader joins to strengthen R&D, with sizable equity package
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact